Nathanael L. Dirks, Pharm.D., Ph.D.

Principal Scientist II

Nathanael joined Metrum in 2010 after receiving his Pharm.D. and Ph.D. (Pharmaceutical Sciences). In his tenure at Metrum, Nathanael has applied both clinical pharmacy knowledge and pharmacometric methods to PK/PD modeling and simulation analyses and strategic decision making at all stages of drug development. His clinical experience spans a broad range of small molecule and biologic therapeutics in a number of therapeutic areas with particular emphasis in pediatric pharmacology, rare diseases, pain management, and inflammatory diseases.

Recent publications by this scientist

Population pharmacokinetics of vedolizumab in Asian and non-Asian patients with ulcerative colitis and Crohn’s disease.

January 13, 2021

Okamoto H, Dirks NL, Rosario M, Hori T, Hibi T. Intest Res. 2021;19(1):95-105. doi:10.5217/ir.2019.09167.

View More

Vedolizumab exposure levels and clinical outcomes in ulcerative colitis: determining the potential for dose optimisation

January 29, 2019

Osterman MT, Rosario M, Lasch K, Barocas M, Wilbur JD, Dirks NL, Gastonguay MR. Aliment Pharmacol Ther. 49(4):408–18. February 2019.

View More

Corrigendum: Exposure-efficacy relationships for vedolizumab induction therapy in patients with ulcerative colitis or Crohn’s disease

March 28, 2018

Rosario M, French JL, Dirks NL, Sankoh S, Parikh A, Yang H, Danese S, Colombel JF, Smyth M, Sandborn WJ, Feagan BG, Reinisch W, Sands BE, Sans M, Fox I. J Crohns Colitis 12 (4): 510. 2018 Mar 28.

View More